ATx201

Phase II – 40 Patients:

  • Place: Department of Clinical Pharmacology, Medical University of Vienna
  • PI: Prof. Markus Zeitlinger, (Advisors: Prof. Emma Guttman, Prof. Georg Stingl)
  • Prospective, randomized, double-blind, placebo controlled study
  • 40 atopic dermatitis patients with S. aureus colonizations
  • Split body design
  • 7-day treatment, dose optimization
  • Safety and efficacy
  • Microbiological endpoints: Reduced colonization of S. aureus

For more information about this study please visit clinicaltrialsregister.eu and clinicaltrials.gov

 

Learn more